Mostrando 3 resultados de: 3
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
ArticleAbstract: Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability ofPalabras claves:Autores:Alyamani M., Bishop A., Bunch D., Dreicer R., Garcia J., Li Z., Liu J., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopusAbiraterone inhibits 3β-hydroxysteroid dehydrogenase: A rationale for increasing drug exposure in castration-resistant prostate cancer
ArticleAbstract: Purpose: Treatment with abiraterone (abi) acetate prolongs survival in castration-resistant prostatePalabras claves:Autores:Chang K.H., Evaul K., Li R., Liu J., Richard J. Auchus, Sharifi N., Sharma K.K., Yoshimoto J.A.Fuentes:scopusXA gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer
ArticleAbstract: Growth of prostate cancer cells is dependent upon androgen stimulation of the androgen receptor (AR)Palabras claves:Autores:Chang K.H., Guo X., Kapur P., Kuri B., Li R., Liu J., Lotan Y., Mirzaei H., Nelson P.S., Richard J. Auchus, Roehrborn C.G., Sharifi N., Vessella R.Fuentes:scopus